Living mapping and living systematic review of Covid-19 studies

Studies registered

5650

Registered studies

1780

Randomized Trials (excluding Traditional Chinese Medicine trials)
994 RCTs recruiting

Results

45812

Records screened

Randomized Controlled trials

Weekly update: September 14, 2020 to September 18, 2020

Over the past week we have screened 4185 records.

On September 2, we have updated the study protocol with respect to:

Type of study: Given the increase in the number of randomized controlled trials, we decided to stop extracting data from Non-Randomized Studies.

Change in outcome: We will not collect data on the outcome 'recovery' as the definition provided by authors was too heterogeneous and redundant with the outcome 'clinical improvement'.

We identified and now report seven new RCTs on our website:

Agarwal et al, evaluating Convalescent plasma versus standard of care

Avendano-Sola et al, Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial

Rosas et al, Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia

Wang et al, Tocilizumab Ameliorates the Hypoxia in COVID-19 Moderate Patients with Bilateral Pulmonary Lesions: A Randomized, Controlled, Open-Label, Multicenter Trial

Rahmani et al, Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial

Lopes et al, Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial

Entrenas Castillo et al, evaluating Vitamin D versus standard of care

We present this week a new page presenting the mapping of vaccine trials and a page presenting the living systematic review of vaccine randomized controlled trials We identified seven trials assessing several potential vaccines for COVID19 and we present data on one trial:

Zhu et al, Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

We have also included and presently extracting four new RCTs comparisons.

Cheng et al, evaluating Recombinant human granulocyte colony-stimulating factor (rhG-CSF) versus standard of care

Chowdhury et al, evaluating Ivermectin + Doxycycline versus Hydroxychloroquine +Azithromycin ,

Delgado-Enciso et al, evaluating Nebulized and/or Intravenous Neutral Electrolyzed Saline,

Farahani et al, evaluating corticosteroids.

Gharebaghi et al, evaluating intravenous immunoglobulin gamma ,

Li et al, evaluating Bromhexine versus standard of care ,

Some RCTs were extracted and pending awaiting author’s reply due to missing outcome data.

To receive updates on our project and research findings, please subscribe to our digest, we will share with you new RCT results and other interesting news.

Our main activities

We are performing a living mapping of ongoing research followed by a living network meta-analysis of study results as soon as they are available.

We are searching and extracting data from RCTs registered in ICTRP once a week (the WHO updates its registry every Wednesday).
We are updating the living mapping and evidence synthesis on our website once a week (every Friday).
A living mapping of studies registered is now available: it is possible to filter studies by type of pharmacological treatment, registration date, study aim, severity scale. An interactive map showing the clinical trials per country is also available. This data visualization was developed by a team from the LIRIS laboratory (CNRS/École Centrale de Lyon) in the context of a large collaboration with the CNRS. Several other teams from CNRS have offered their help for this project to contribute to the fight against Covid-19. As a result, more graphs and tables are currently being developed and will be soon available on our website.
We are screening the L.OVE platform and the the Cochrane COVID-19 Study register platform every day to identify results of RCTs.
We are collecting data from all RCTs identified. The main characteristics of trials, including a complete description of the assessment of each risk of bias domain with support for judgement and forest plots are available here. The Evidence profile and Summary of Findings (SoF) tables for most of the comparisons are also available online and the missing ones are currently being designed.
We are contacting all investigators of ongoing trials to obtain the trial protocol and results as soon as available.
Several databases of the reference list for modeling studies, observational studies, RCTs and non-RCT studies and studies we excluded from our systematic review are available online . Users of datasets published by the Covid-NMA project are required to acknowledge the source with an appropriate citation. We recommend using the following format: Authors. (Year). Dataset title [Data set]. Repository. DOI

For more information on our methods see our protocol here.

This work received some funding from the Agence Nationale de la Recherche (ANR), the World Health Organization (WHO), Cochrane France, Center of Research in Epidemiology and StatisticS (CRESS), Centre d’Epidémiologie Clinique (GHU Cochin, Hôtel Dieu, Assistance Publique Hôpitaux de Paris (APHP) and Université de Paris) and the Federal Ministry of Health, Germany

We encourage all investigators of Randomized Controlled Trials to contact us as soon as they have results available.